CONMED Corporation (CNMD) vs Nuvalent Inc (NUVL)
The same free fields, in the same order, for both companies, so a figure on one line can be read straight across.
This page states measurements and nothing else. It does not rank the two companies, name one of them, or draw a conclusion from the figures.
Data as of Oct 27, 2026, for both companies.
The figures, field by field
A dash means the snapshot carries no figure for that company on that line. A line is dropped only when neither company has it, so a dash beside a figure is a fact about coverage, not about either company.
| CNMD | NUVL | |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Medical Devices | Biotechnology |
| Size band | SMALL | MID |
| Listing | NYSE | Nasdaq GM |
| Country | United States | United States |
| Theme | medical-devices | oncology |
| Price and returns | ||
| Last close | $47.68 | $123.96 |
| Return · 1 week | +3.54% | 0.00% |
| Return · 1 month | +2.58% | 0.00% |
| Return · 3 months | +7.75% | 0.00% |
| Return · year to date | +17.67% | +22.93% |
| Return · 1 year | +0.68% | +26.87% |
| Distance from the 52-week highThe last close measured against the highest close of the past 52 weeks. | −11.14% | −0.02% |
| 52-week high | $53.66 | $123.99 |
| 52-week low | $31.44 | $87.30 |
| Size and turnover | ||
| Market value · USDConverted to US dollars, so two companies listed in different currencies sit under one heading. | $1.43B | $9.79B |
| Turnover · median day, USDThe median value traded in a session over the past 50 sessions. | $15.49M | $149.69M |
| Employees | 3,900 | 234 |
| Valuation | ||
| Price to earnings · trailing | 26.62× | n/a (negative earnings) |
| Price to earnings · forward | 10.30× | n/a (negative forward earnings) |
| Price to sales | 1.08× | — |
| Price to book | 1.42× | 8.33× |
| Enterprise value to EBITDA | 9.99× | — |
| Enterprise value to revenue | 1.66× | — |
| PEG ratio | 1.84 | — |
| Earnings per share · trailing | 1.85 | -6.06 |
| Profitability | ||
| Gross margin | 55.79% | — |
| Operating margin | 14.64% | 0.00% |
| Profit margin | 4.12% | — |
| Return on equity | 5.53% | −41.19% |
| Return on assets | 4.14% | −22.51% |
| Growth | ||
| Revenue growth | +0.30% | — |
| Earnings growth | +11.20% | — |
| Balance sheet and payout | ||
| Debt / equity (%) | 80.11 | — |
| Current ratio | 1.48 | 16.14 |
| Dividend yield | 0.00% | — |
| Payout ratio | 10.81% | 0.00% |
| Trend and volatility | ||
| RSI · 14 | 53.78 | — |
| ADX · 14 | 19.60 | — |
| 50-day average | $47.44 | — |
| 200-day average | $41.33 | — |
| Average true range · share of priceAverage true range over 14 sessions, stated as a share of the last close, so it can be read across two share prices. | 3.55% | — |
The full CNMD analysis
Everything this table leaves out for CONMED Corporation: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the CNMD argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full CNMD analysisThe full NUVL analysis
Everything this table leaves out for Nuvalent Inc: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the NUVL argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full NUVL analysis